瑞莎珠单抗诱导治疗100例克罗恩病的有效性与安全性:GETAID多中心队列研究
该研究回顾性纳入22个法国GETAID中心的100例难治性腔内型克罗恩病患者,均曾暴露于抗TNF制剂、维得利珠单抗和乌司奴单抗。第12周无激素临床缓解率为45.8%,临床缓解率58%,临床应答率78.5%,生化缓解率50%。20例患者发生20起不良事件,其中7起为严重不良事件。
要点
- 第12周无激素临床缓解率45.8%,临床应答率78.5%,生化缓解率50%。
- 基线有客观炎症征象者(n=79)第12周无激素临床缓解率为39.2%。
- 乌司奴单抗继发失效史与第12周临床缓解显著相关(OR 2.80,95%CI 1.07-7.82,p=0.041)。
核心结论
- 在高度难治且包括乌司奴单抗在内的多种药物既往失败的腔内型克罗恩病队列中,瑞莎珠单抗诱导治疗使约四分之三患者获得临床应答、约半数患者获得无激素临床缓解。
研究设计与样本
- 回顾性多中心队列研究,纳入2021年5月至2022年5月法国22个GETAID中心所有接受瑞莎珠单抗治疗的难治性腔内型克罗恩病患者,共100例。
主要发现
- 所有患者既往暴露于抗TNF制剂,94例暴露于维得利珠单抗,98例暴露于乌司奴单抗,61例有既往肠切除史;除3例外(97%)接受600 mg瑞莎珠单抗静脉诱导,于第0-4-8周给药。
- 第12周无激素临床缓解(Harvey-Bradshaw评分<5)率为45.8%,临床缓解率58%,临床应答率78.5%;基线有客观炎症征象者(n=79)第12周无激素临床缓解率为39.2%。
- 生化缓解(C反应蛋白≤5 mg/L)率为50%;6例因疗效不足在第12周访视前停用瑞莎珠单抗,6例需克罗恩病相关住院,3例接受肠切除。
- 多变量分析中,仅乌司奴单抗继发失效史(相对于原发失效)与第12周临床缓解显著相关(OR 2.80,95%CI 1.07-7.82,p=0.041)。
- 20例患者发生20起不良事件,包括7起严重不良事件,对应6例克罗恩病加重和1例严重高血压。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phase III trials have demonstrated the efficacy of risankizumab in moderate-to-severe Crohn's disease (CD), but no real-world data are currently available. We aimed to assess the short-term effectiveness and safety of risankizumab in patients with CD. METHODS: From May 2021 to May 2022, all patients with refractory luminal CD treated with risankizumab in 22 French GETAID centres were retrospectively included. The primary endpoint was steroid-free clinical remission at week 12 (Harvey-Bradshaw [HB] score <5). Secondary endpoints included clinical response (≥3-point decrease of HB score and/or (HB) score <5), biochemical remission (CRP ≤ 5 mg/L), need for CD-related surgery and adverse events. RESULTS: Among the 100 patients included, all have been previously exposed to anti-TNF agents, 94 to vedolizumab, 98 to ustekinumab (all exposed to at least three biologics) and 61 had a previous intestinal resection. All but three (97%) received a 600 mg risankizumab intravenous induction at weeks 0-4-8. At week 12, steroid-free clinical remission was observed in 45.8% of patients, clinical remission in 58% and clinical response in 78.5%. In subgroup analysis restricted to patients with objective signs of inflammation at baseline (n = 79), steroid-free clinical remission at week 12 was observed in 39.2% of patients. Biochemical remission was observed in 50% of patients. Six patients discontinued risankizumab before the week 12 visit due to lack of efficacy. CD-related hospitalisation was needed in six patients, and three underwent intestinal resection. In multivariable analysis, only a history of ustekinumab loss of response (vs primary failure) (odds ratio (OR), 2.80; 95% CI: 1.07-7.82; p = 0.041) was significantly associated with clinical remission at week 12. Twenty adverse events (AE) occurred in 20 patients including 7 serious AE corresponding to 6 CD exacerbation and one severe hypertension. CONCLUSION: In a cohort of highly refractory patients with luminal CD and multiple prior drug failures including ustekinumab, risankizumab induction provided a clinical response in about 3 out of 4 patients and steroid-free clinical remission in about half of patients.
引用
- Fumery M, Defrance A, Roblin X, et al. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Aliment Pharmacol Ther. 2022. PMID: 36534763. doi:10.1111/apt.17358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。